Egfr Gene Mutation Clinical Trials
3 recruiting trials for Egfr Gene Mutation. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Egfr Gene Mutation clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Second Xiangya Hospital of Central South University (1), Instituto Nacional de Cancerologia de Mexico (1), Apollomics Inc. (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Genomic profiles detection (other, 1 trial), followed by circulating tumor DNA detection, Nitroglycerin.
Track Egfr Gene Mutation trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive...
Lung cancer is currently the world's largest malignant tumor for cancer-related deaths with non-small cell lung cancer (NSCLC) accounting for 80%-85%. Epidermal growth factor...
Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.
The goal of this interventional phase III clinical trial is to evaluate objective intracranial response rate (iORR) after a treatment with total cranial radiation therapy plus...
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Egfr Gene Mutation, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Egfr Gene Mutation, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Egfr Gene Mutation, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.